SARS-CoV2 antibody tests: not suited for individual diagnosis?
An international research consortium provides data demonstrating that SARS-CoV-2 antibody tests are only useful for population-based analyses.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1165 entries already.
Entries by Thomas Gabrielczyk
Vaccine to protect from any viral infection
/in News/by Thomas GabrielczykTwo companies have presented a novel vaccination concept that might protect risk groups from new SARS-CoV-2 variants.
Abivax bags 36m fund for COVID-19 programme
/in News/by Thomas GabrielczykFrench Abivax SA has received a 36m non-dilutive funding from Bpifrance for its ABX464 Covid-19 programme.
4Teen4s DPP3 predicts burn mortality
/in News/by Thomas Gabrielczyk4TEEN4 Pharmaceuticals GmbH published data suggesting that high plasma levels of dipeptidyl peptidase 3 were indicative for upcoming multiple organ failure in burn patients.
S-Protein: Glycosylation pattern revealed
/in News/by Thomas GabrielczykBritish researchers have deciphered the glycosylation pattern of the viral spike protein of SARS-CoV-2 laying the foundation for vaccine development.
Newron terminates sarizotan development in Rett syndrome
/in News/by Thomas GabrielczykNewron Pharmaceuticals S.p.A.s Sarizotan failed to meet efficacy endpoints in the Phase III STARS study.
Bone Therapeutics bags 11m
/in News/by Thomas GabrielczykBelgian Bone Therapeutics SA has secured 11m to foster development of its late stage pipeline candidates.
Cevec launches ELEVECTA platform
/in News/by Thomas GabrielczykCevec Pharmaceuticals GmbH has launched a new, scalable production platform for AAV gene therapy vectors.
Artes enters COVID-19 vaccine race
/in News/by Thomas GabrielczykGerman vaccine developer ARTES Biotechnology GmbH will develop a COVID-19 subunit vaccine based on virus-like particles (VLP), which include two proteins of SARS-CoV-2.
Bayer, Novartis, and Trump convicted by Nature
/in News/by Thomas GabrielczykThe politically overhyped use of old malaria drugs in combination with COVID-19-specific candidates has been demonstrated to be dangerous, reports Nature Medicine.